Substance P fragments and striatal endogenous dopamine outflow: interaction with substance P

Accumulating evidence shows that N- and C-terminal substance P fragments have significant biological activity. Substance P(1–9) and substance P(6–11) have been reported to be major substance P metabolites in rat striatum. We investigated the effects of these fragments on endogenous dopamine outflow in rat striatal slices. Substance P-(1–9) and substance P-(6–11) induced a significant increase in dopamine outflow at 0.1 and 1 nM. The effects of substance P-(6–11) (1 nM) were reversed by the tachykinin NK₁ antagonist WIN 51,708 (17β-hydroxy-17α-ethynyl-5α-androstano[3,2-b]pyrimido[1,2-a]benzimidazole) (2.5 nM), whereas the effects of substance P-(1–9) were not modified by the antagonist. Substance P-(1–9) and substance P-(6–11) (1 nM) did not increase the dopamine overflow induced by 25 mM KCl. The effects of the two fragments were reversed by the muscarinic antagonist atropine (1 μM) but not by nicotinic antagonists dihydro-β-erythroidine (0.5 μM) and pempidine (10 μM). The co-incubation of tissue with substance P and each fragment in a 1/1 or 10/1 ratio of substance P to metabolite revealed a negative interaction between parent and fragments. A similar pattern was observed when substance P was co-administered with the active fragments substance P(1–4), substance P(1–7), substance P(5–11) and substance P(8–11). The data show that substance P-(1–9) and substance P-(6–11) have modulatory effects similar to substance P. However, the presence of active substance P metabolites does not appear to amplify the signal mediated by the parent peptide.